Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | HTT | P42858 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CASP6 | P55212 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17747815 | 0.98 | SMN1; SMN2 (0.61) | SMN1; SMN2HTTLMNANOD2MEN1 | |
| SCHEMBL5754852 | 0.87 | L3MBTL1 (0.69) | SMN1; SMN2HTTLMNANOD2MEN1 | |
| SCHEMBL1353061 | 0.87 | HTT (0.66) | SMN1; SMN2HTTLMNANOD2MEN1 | |
| SCHEMBL1354636 | 0.87 | SMN1; SMN2 (0.59) | SMN1; SMN2HTTLMNANOD2MEN1 | |
| SCHEMBL10126443 | 0.87 | GAA (0.76) | SMN1; SMN2HTTLMNANOD2MEN1 | |
| SCHEMBL20456913 | 0.87 | HTT (0.66) | SMN1; SMN2HTTLMNANOD2MEN1 | |
| SCHEMBL14324542 | 0.87 | ALDH1A1 (0.76) | SMN1; SMN2HTTLMNANOD2MEN1 | |
| SCHEMBL14236801 | 0.87 | ALDH1A1 (0.76) | SMN1; SMN2HTTLMNANOD2MEN1 | |
| SCHEMBL15172174 | 0.87 | ALDH1A1 (0.76) | SMN1; SMN2HTTLMNANOD2MEN1 | |
| SCHEMBL15754986 | 0.86 | ALDH1A1 (0.56) | SMN1; SMN2HTTLMNANOD2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776988-B2 | Pyrazolylbenzo[d]imidazole derivatives | CELON PHARMA S.A. (PL) | 2017-10-03 | — | — | US | disclosed |
| US-9776988-B2 | Pyrazolylbenzo[d]imidazole derivatives | CELON PHARMA S.A. (PL) | 2017-10-03 | — | — | US | disclosed |
| US-9776988-B2 | Pyrazolylbenzo[d]imidazole derivatives | CELON PHARMA S.A. (PL) | 2017-10-03 | — | — | US | disclosed |
| EP-2970210-B1 | PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES | Celon Pharma Sa (PL) | 2017-01-04 | — | — | EP | disclosed |
| EP-2970210-B1 | PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES | Celon Pharma Sa (PL) | 2017-01-04 | — | — | EP | disclosed |
| US-20160039794-A1 | PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES | CELON PHARMA S.A. (PL) | 2016-02-11 | — | — | US | disclosed |
| US-20160039794-A1 | PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES | CELON PHARMA S.A. (PL) | 2016-02-11 | — | — | US | disclosed |
| US-20160039794-A1 | PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES | CELON PHARMA S.A. (PL) | 2016-02-11 | — | — | US | disclosed |
| EP-2970210-A1 | PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES | CELON PHARMA S.A. (PL) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014141015-A1 | PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES | CELON PHARMA S.A. (PL) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014141015-A1 | PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES | CELON PHARMA S.A. (PL) | 2014-09-18 | — | — | WO | disclosed |
| US-8778936-B2 | Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8399442-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20120190673-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-07-26 | — | — | US | disclosed |
| US-8110573-B2 | Enzyme inhibitors; Cyclin-Dependent Kinases (CDK), Glycogen Synthase Kinases (GSK); -cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea salt for example; anticancer agents | ASTEX THERAPEUTICS LIMITED (GB) | 2012-02-07 | — | — | US | disclosed |
| US-20100004232-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (UK) | 2010-01-07 | — | — | US | disclosed |
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004232-A1 | Pharmaceutical Compounds | ERBB3, ABL1, RET | SMN1; SMN2 3461/4885HTT 3102/4885LMNA 3862/4885 |
| US-20160039794-A1 | PYRAZOLYLBENZO[D]IMIDAZOLE DERIVATIVES | NR0B2, NR2C2, NR4A3 | SMN1; SMN2 3327/4885HTT 4737/4885LMNA 1401/4885 |
| US-20120190673-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | CDK3, CDK1, AURKA | SMN1; SMN2 2569/4885HTT 3641/4885LMNA 634/4885 |
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | CDK3, CDK1, AURKA | SMN1; SMN2 2569/4885HTT 3641/4885LMNA 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.